RXRX
NASD Recursion Pharmaceuticals, Inc. Class A$4.01 ↑ +0.00 (+0.00%) Trading Up from the previous close of $4.01, $0.36 below the day’s high of $4.37
- YTD change
- -1.96%
- vs 20-day SMA
- +2.04%
- vs 200-day SMA
- +12.24%
Price ranges
Price & Performance
+0.59 (+17.25%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 90.6% away from all-time highs of $42.81
- RXRX is down 2% since the beginning of the year
- RXRX is down 25% over the past 12 months
- RXRX is up 25% over the past 1 month
- 37% of all RXRX investors are betting against RXRX
RXRX reads not so good: price sits above both the 20- and 200-day averages, the 12-month move is -27.5%.
- Previous minute
- +$0.01
- Last hour
- -$0.01
- Last 5 days
- -2.67%
- vs 8-day SMA
- -6.50%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
